search
Back to results

Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients (OPERA)

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Phase 4
Locations
Japan
Study Type
Interventional
Intervention
Clopidogrel
Sponsored by
Associations for Establishment of Evidence in Interventions
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Disease, Cardiovascular Disease, Arteriosclerosis, Arterial Occlusive Disease, Vascular Disease, Clopidogrel, Platelet Aggregation Inhibitors

Eligibility Criteria

20 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Clinical inclusion criteria

    • Patient over age 20 years.
    • Patient who is clinically indicated for PCI by stenting at least in one coronary lesion that is visually confirmed by coronary angiography.
    • Patient who has agreed to conditions after receiving an explanation about the contents of the present clinical study and who has signed the consent form approved by the ethical review board at each study site.
    • Patient who has agreed to undergo all clinical FUs listed in the present protocol.

  2. Coronary angiographic inclusion criteria:

    • Patient who has a > 50% occlusion or stenosis that is visually confirmed by coronary angiography in a native coronary artery > 2.5 mm in diameter and in whom the relevant coronary artery has an anatomical structure that is eligible for PCI with Endeavor Zotarolimus-eluting stent.

Exclusion Criteria:

  1. Clinical exclusion criteria

    • Patient over age 85 years.
    • Patient with ST elevation MI who requires primary or rescue PCI and whose performance status falls under any of the exclusion criteria.
    • Patient with cardiogenic shock.
    • Patient who underwent stent treatment with BMS in other lesions within 6 months prior to the conduct of index PCI of the target vessel.
    • Patient who has undergone some treatment with DES for coronary lesions.
    • Patient who is scheduled to undergo elective surgery within 12 months after index PCI.
    • Patient whose left ventricular ejection fraction (LVEF) is < 40%.
    • Patient with a hemorrhagic predisposition or a history of coagulation abnormality
    • Patient in whom the total number of deployed stents exceeds 4,regardless of the number of lesions and the number of affected branches.
    • Patient with a verified history of CVA before stenting.
    • Patient with a verified history of active peptic ulcer or upper gastrointestinal tract bleeding before Stenting.
    • Patient showing impaired renal function. (serum creatinine concentration: > 1.8 mg/dL)
    • Patient with known contraindications for aspirin or clopidogrel. (the physician should assess tolerability within the range of routine medical care)
    • Patient with a known disorder who has a life expectancy of less than 12 months.
    • Patient who is incompetent to adhere to all clinical FUs listed in the present protocol.

  2. Angiographic exclusion criteria:

    • Lesions located within the saphenous venin graft (SVG).
    • Unprotected lesions in the left coronary trunk.
    • Lesions of in-stent restenosis in previously deployed DES or BMS.
    • Lesions with an anatomical structure of the coronary artery that is not eligible for treatment by the deployment of Endeavor ZES.

Sites / Locations

  • Asahi General Hospital
  • Kimitsu Chuo Hospital
  • Fukui Cardiovascular Center
  • Fukuoka City Hospital
  • Fukuoka City Medical Association Hospital
  • Fukuoka Red Cross Hospital
  • University of Occupational and Environmental Health
  • National Hospital Organization Fukuoka-Higashi Medical Center
  • Gifu Heart Center
  • Fukuyama City Hospital
  • Hiroshima Railway Hospital
  • Tsuchiya General Hospital
  • Engaru-Kosei General Hospital
  • Hyogo Prefectural Amagasaki Hospital
  • Kansai Rosai Hospital, Cardiovascular Center
  • Kobe City Medical Center General Hospital
  • Shakaihoken Kobe Central Hospital
  • Miki City Hospital
  • Hyogo College of Medicine
  • Meiwa General Hospital
  • Hyogo Prefectural Awaji Hospital
  • Kanazawa University Hospital
  • Kaisei General Hospital
  • Kagoshima University Hospital
  • Tenyoukai Central Hospital
  • Ebina General Hospital
  • Fujisawa City Hospital
  • Kawasaki Municipal Tama Hospital
  • St. Marianna University of Medicine, Toyoko Hospital
  • St. Marianna University School of Medicine
  • Synthesis Shinkawahashi Hospital
  • Odawara Cardiovascular Hospital
  • Kitazato University School of Medicine
  • Sagamihara Kyodo Hospital
  • Kanagawa Cardiovascular and Reppiratory Center
  • Saiseikai Yokohama Tobu Hospital
  • Showa University Fujigaoka Hospital
  • St. Marianna University of Medicine, Yokohama City West Hospital
  • Yokohama City University Hospital
  • Yokohama City UNiversity Medical Center
  • Kumamoto Chuo Hospital
  • Kumamoto Red Cross Hospital
  • National Hospital Organization Kumamoto Medical Center
  • Saiseikai Kumamoto Hospital
  • Sugimura Hospital
  • Ijinkai Takeda General Hospital
  • Koseikai Takeda Hospital
  • Kyoto Second Red Cross Hospital
  • Gakken The Holy City Medical Association Hospital
  • Uji Tokushukai Hospital
  • Matsuzaka Central General Hospital
  • Suzuka Central General Hospital
  • Mie Heart Center
  • Mie University Hospital
  • Nagasaki University Graduate School of Biomedical Science
  • Kawasaki Medical School
  • National Hospital Organization Okayama Medical Center
  • The Sakakibara Heart Institute of Okayama
  • Ohama Daiichi Hospital
  • Nakagami Hospital
  • Okinawa Nanbu Tokushukai Hospital
  • Urasoe General Hospital
  • Kawachi General Hospital
  • Kansai Medical University Hirakata Hospital
  • Kansai Medical University Takii Hospital
  • Komatsu General Hospital
  • Higashi-sumiyoshi Morimoto Hospital
  • Nissay Hospital
  • Osaka City General Hospital
  • Osaka City University, Graduate School of Medicine
  • Osaka Ekisaikai Hospital
  • Osaka General Hospital of West Japan Railway Campany
  • Osaka General Medical Center
  • Osaka Gyoumeikan Hospital
  • Osaka Police Hospital
  • Sakurabashi Watanabe Hospital
  • Bell Land General Hospital
  • Mimihara General Hospital
  • National Cerebral and Cardiovascular Center
  • Osaka University Graduate School of Medicine
  • Saiseikai Senri Hospital
  • Hokusetsu General Hospital
  • Midorigaoka Hospital
  • Department of Cardiovascular Medicine, Saga University
  • Mashiko Hospital
  • Saitama Medical Center, Jichi Medical University
  • Kusatsu Heart Center
  • Shiga Medical Center for Adults
  • Omihachiman Community Medical Center
  • Biwako Ohashi Hospital
  • Hamamatsu Medical Center
  • Seirei Hamamatsu General Hospital
  • Juntendo University Shizuoka Hospital
  • Tokushima Red Cross Hospital
  • Ayase Heart Hospital
  • Juntendo University Hospital
  • The University of Tokyo Hospital
  • St. Luke's International Hospital
  • Sakakibara Heart Institute
  • Tokyo Metroporitan Tama Medical Center
  • Itabashi Chuo Medical Center
  • Nihon University School of Medicine
  • Teikyo University Hospital
  • Tokyo Metroporitan Geriatric Hospital and Institute of Gerontology
  • Toho University Medical Center Ohashi Hospital
  • The Cardiovascular Institute
  • The Jikei University Hospital
  • JR Tokyo General Hospital
  • NTT Medical Center Tokyo
  • Tottri University
  • Shuto General Hospital
  • Non-profit organization Associations for Establishiment of Evidence in Interventions

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Short-term DAPT group

Long-term DAPT group

Arm Description

1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)

1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)

Outcomes

Primary Outcome Measures

NACCE (Net adverse clinical and cerebral event)
NACCE is defined as a composite endpoint consisting of death from some causes (including cardiac death and noncardiac death), myocardial infarction (Q-wave MI and non-Q wave MI), cerebral vascular accident, and major bleeding (as per the modified version of REPLACE-2 criteria for bleeding and as per GUSTO criteria for bleeding).

Secondary Outcome Measures

Stent thrombosis
Incidence of stent thrombosis as per the definition by academic research council
MACE (major adverse cardiac events)
Incidence of MACE at months 1, 3, 6, 9, and 12 after stenting. MACE is defined as a composite endpoint consisting of cardiac death from some causes (including cardiac and noncardiac death), MI (Q-wave MI and non-Q wave MI), TLR, and coronary artery bypass graft (CABG).
TVR (target vessel revascularization)
Incidence of target vessel revascularization at months 9 and 12 after stenting.
TLR (target lesion revascularization)
Incidence of target lesion revascularization at months 9 and 12 after stenting.
DAPT compliance
Duration of DAPT and patient compliance.
Hemorrhagic complications
Incidence of hemorrhagic complications. (as per the modified version of REPLACE-2 criteria for bleeding and as per GUSTO criteria for bleeding)

Full Information

First Posted
March 29, 2011
Last Updated
January 5, 2016
Sponsor
Associations for Establishment of Evidence in Interventions
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT01325935
Brief Title
Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients
Acronym
OPERA
Official Title
Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
December 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Associations for Establishment of Evidence in Interventions
Collaborators
Medtronic

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A prospective multicenter registry in real-world Japanese patients undergoing DAPT for three months after stenting. To assess the long-term safety of Endeavor Zotarolimus-eluting stent through noninferiority in the primary endpoint between two different continuous regimen (three and twelve months) groups of DAPT after stenting with Endeavor Zotarolimus-eluting stent in real-world Japanese patients and to examine the optimal duration of DAPT after stenting with Endeavor Zotarolimus-eluting stent. The long-term DAPT group in the present clinical study (to be appropriated from the post-marketing surveillance of Endeavor) should consist of consecutive patients undergoing DAPT for twelve months after stenting, while the short-term DAPT group (to be newly registered in the present clinical study) should consist of patients who are instructed to undergo DAPT for three months after stenting.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Disease, Cardiovascular Disease, Arteriosclerosis, Arterial Occlusive Disease, Vascular Disease, Clopidogrel, Platelet Aggregation Inhibitors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1187 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Short-term DAPT group
Arm Type
Experimental
Arm Description
1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
Arm Title
Long-term DAPT group
Arm Type
No Intervention
Arm Description
1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
Intervention Type
Drug
Intervention Name(s)
Clopidogrel
Intervention Description
DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
Primary Outcome Measure Information:
Title
NACCE (Net adverse clinical and cerebral event)
Description
NACCE is defined as a composite endpoint consisting of death from some causes (including cardiac death and noncardiac death), myocardial infarction (Q-wave MI and non-Q wave MI), cerebral vascular accident, and major bleeding (as per the modified version of REPLACE-2 criteria for bleeding and as per GUSTO criteria for bleeding).
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Stent thrombosis
Description
Incidence of stent thrombosis as per the definition by academic research council
Time Frame
12 months
Title
MACE (major adverse cardiac events)
Description
Incidence of MACE at months 1, 3, 6, 9, and 12 after stenting. MACE is defined as a composite endpoint consisting of cardiac death from some causes (including cardiac and noncardiac death), MI (Q-wave MI and non-Q wave MI), TLR, and coronary artery bypass graft (CABG).
Time Frame
1, 3, 6, 9 and 12 months
Title
TVR (target vessel revascularization)
Description
Incidence of target vessel revascularization at months 9 and 12 after stenting.
Time Frame
9 and 12 months
Title
TLR (target lesion revascularization)
Description
Incidence of target lesion revascularization at months 9 and 12 after stenting.
Time Frame
9 and 12 months
Title
DAPT compliance
Description
Duration of DAPT and patient compliance.
Time Frame
12 months
Title
Hemorrhagic complications
Description
Incidence of hemorrhagic complications. (as per the modified version of REPLACE-2 criteria for bleeding and as per GUSTO criteria for bleeding)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical inclusion criteria Patient over age 20 years. Patient who is clinically indicated for PCI by stenting at least in one coronary lesion that is visually confirmed by coronary angiography. Patient who has agreed to conditions after receiving an explanation about the contents of the present clinical study and who has signed the consent form approved by the ethical review board at each study site. Patient who has agreed to undergo all clinical FUs listed in the present protocol. Coronary angiographic inclusion criteria: Patient who has a > 50% occlusion or stenosis that is visually confirmed by coronary angiography in a native coronary artery > 2.5 mm in diameter and in whom the relevant coronary artery has an anatomical structure that is eligible for PCI with Endeavor Zotarolimus-eluting stent. Exclusion Criteria: Clinical exclusion criteria Patient over age 85 years. Patient with ST elevation MI who requires primary or rescue PCI and whose performance status falls under any of the exclusion criteria. Patient with cardiogenic shock. Patient who underwent stent treatment with BMS in other lesions within 6 months prior to the conduct of index PCI of the target vessel. Patient who has undergone some treatment with DES for coronary lesions. Patient who is scheduled to undergo elective surgery within 12 months after index PCI. Patient whose left ventricular ejection fraction (LVEF) is < 40%. Patient with a hemorrhagic predisposition or a history of coagulation abnormality Patient in whom the total number of deployed stents exceeds 4,regardless of the number of lesions and the number of affected branches. Patient with a verified history of CVA before stenting. Patient with a verified history of active peptic ulcer or upper gastrointestinal tract bleeding before Stenting. Patient showing impaired renal function. (serum creatinine concentration: > 1.8 mg/dL) Patient with known contraindications for aspirin or clopidogrel. (the physician should assess tolerability within the range of routine medical care) Patient with a known disorder who has a life expectancy of less than 12 months. Patient who is incompetent to adhere to all clinical FUs listed in the present protocol. Angiographic exclusion criteria: Lesions located within the saphenous venin graft (SVG). Unprotected lesions in the left coronary trunk. Lesions of in-stent restenosis in previously deployed DES or BMS. Lesions with an anatomical structure of the coronary artery that is not eligible for treatment by the deployment of Endeavor ZES.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Takaaki Isshiki, M.D.
Organizational Affiliation
Teikyo University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Shinsuke Nanto, M.D.
Organizational Affiliation
Osaka University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Masato Nakamura, M.D.
Organizational Affiliation
Toho University Ohashi Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asahi General Hospital
City
Asahi City
State/Province
Chiba
Country
Japan
Facility Name
Kimitsu Chuo Hospital
City
Kisarazu City
State/Province
Chiba
Country
Japan
Facility Name
Fukui Cardiovascular Center
City
Fukui City
State/Province
Fukui
Country
Japan
Facility Name
Fukuoka City Hospital
City
Fukuoka City
State/Province
Fukuoka
Country
Japan
Facility Name
Fukuoka City Medical Association Hospital
City
Fukuoka City
State/Province
Fukuoka
Country
Japan
Facility Name
Fukuoka Red Cross Hospital
City
Fukuoka City
State/Province
Fukuoka
Country
Japan
Facility Name
University of Occupational and Environmental Health
City
Kita-Kyushu City
State/Province
Fukuoka
Country
Japan
Facility Name
National Hospital Organization Fukuoka-Higashi Medical Center
City
Koga City
State/Province
Fukuoka
Country
Japan
Facility Name
Gifu Heart Center
City
Gifu City
State/Province
Gifu
Country
Japan
Facility Name
Fukuyama City Hospital
City
Fukuyama City
State/Province
Hiroshima
Country
Japan
Facility Name
Hiroshima Railway Hospital
City
Hiroshima City
State/Province
Hiroshima
Country
Japan
Facility Name
Tsuchiya General Hospital
City
Hiroshima City
State/Province
Hiroshima
Country
Japan
Facility Name
Engaru-Kosei General Hospital
City
Monbetsu-gun
State/Province
Hokkaido
Country
Japan
Facility Name
Hyogo Prefectural Amagasaki Hospital
City
Amagasaki City
State/Province
Hyogo
Country
Japan
Facility Name
Kansai Rosai Hospital, Cardiovascular Center
City
Amagasaki City
State/Province
Hyogo
Country
Japan
Facility Name
Kobe City Medical Center General Hospital
City
Kobe City
State/Province
Hyogo
Country
Japan
Facility Name
Shakaihoken Kobe Central Hospital
City
Kobe City
State/Province
Hyogo
Country
Japan
Facility Name
Miki City Hospital
City
Miki City
State/Province
Hyogo
Country
Japan
Facility Name
Hyogo College of Medicine
City
Nishinomiya City
State/Province
Hyogo
Country
Japan
Facility Name
Meiwa General Hospital
City
Nishinomiya City
State/Province
Hyogo
Country
Japan
Facility Name
Hyogo Prefectural Awaji Hospital
City
Sumoto City
State/Province
Hyogo
Country
Japan
Facility Name
Kanazawa University Hospital
City
Kanazawa City
State/Province
Ishikawa
Country
Japan
Facility Name
Kaisei General Hospital
City
Sakaide City
State/Province
Kagawa
Country
Japan
Facility Name
Kagoshima University Hospital
City
Kagoshima City
State/Province
Kagoshima
Country
Japan
Facility Name
Tenyoukai Central Hospital
City
Kagoshima City
State/Province
Kagoshima
Country
Japan
Facility Name
Ebina General Hospital
City
Ebina City
State/Province
Kanagawa
Country
Japan
Facility Name
Fujisawa City Hospital
City
Fujisawa City
State/Province
Kanagawa
Country
Japan
Facility Name
Kawasaki Municipal Tama Hospital
City
Kawasaki City
State/Province
Kanagawa
Country
Japan
Facility Name
St. Marianna University of Medicine, Toyoko Hospital
City
Kawasaki City
State/Province
Kanagawa
Country
Japan
Facility Name
St. Marianna University School of Medicine
City
Kawasaki City
State/Province
Kanagawa
Country
Japan
Facility Name
Synthesis Shinkawahashi Hospital
City
Kawasaki City
State/Province
Kanagawa
Country
Japan
Facility Name
Odawara Cardiovascular Hospital
City
Odawara City
State/Province
Kanagawa
Country
Japan
Facility Name
Kitazato University School of Medicine
City
Sagamihara City
State/Province
Kanagawa
Country
Japan
Facility Name
Sagamihara Kyodo Hospital
City
Sagamihara City
State/Province
Kanagawa
Country
Japan
Facility Name
Kanagawa Cardiovascular and Reppiratory Center
City
Yokohama City
State/Province
Kanagawa
Country
Japan
Facility Name
Saiseikai Yokohama Tobu Hospital
City
Yokohama City
State/Province
Kanagawa
Country
Japan
Facility Name
Showa University Fujigaoka Hospital
City
Yokohama City
State/Province
Kanagawa
Country
Japan
Facility Name
St. Marianna University of Medicine, Yokohama City West Hospital
City
Yokohama City
State/Province
Kanagawa
Country
Japan
Facility Name
Yokohama City University Hospital
City
Yokohama City
State/Province
Kanagawa
Country
Japan
Facility Name
Yokohama City UNiversity Medical Center
City
Yokohama City
State/Province
Kanagawa
Country
Japan
Facility Name
Kumamoto Chuo Hospital
City
Kumamoto City
State/Province
Kumamoto
Country
Japan
Facility Name
Kumamoto Red Cross Hospital
City
Kumamoto City
State/Province
Kumamoto
Country
Japan
Facility Name
National Hospital Organization Kumamoto Medical Center
City
Kumamoto City
State/Province
Kumamoto
Country
Japan
Facility Name
Saiseikai Kumamoto Hospital
City
Kumamoto City
State/Province
Kumamoto
Country
Japan
Facility Name
Sugimura Hospital
City
Kumamoto City
State/Province
Kumamoto
Country
Japan
Facility Name
Ijinkai Takeda General Hospital
City
Kyoto City
State/Province
Kyoto
Country
Japan
Facility Name
Koseikai Takeda Hospital
City
Kyoto City
State/Province
Kyoto
Country
Japan
Facility Name
Kyoto Second Red Cross Hospital
City
Kyoto City
State/Province
Kyoto
Country
Japan
Facility Name
Gakken The Holy City Medical Association Hospital
City
Sagara-gun
State/Province
Kyoto
Country
Japan
Facility Name
Uji Tokushukai Hospital
City
Uji City
State/Province
Kyoto
Country
Japan
Facility Name
Matsuzaka Central General Hospital
City
Matsuzaka City
State/Province
Mie
Country
Japan
Facility Name
Suzuka Central General Hospital
City
Suzuka City
State/Province
Mie
Country
Japan
Facility Name
Mie Heart Center
City
Taki-gun
State/Province
Mie
Country
Japan
Facility Name
Mie University Hospital
City
Tsu City
State/Province
Mie
Country
Japan
Facility Name
Nagasaki University Graduate School of Biomedical Science
City
Nagasaki City
State/Province
Nagasaki
Country
Japan
Facility Name
Kawasaki Medical School
City
Kurashiki City
State/Province
Okayama
Country
Japan
Facility Name
National Hospital Organization Okayama Medical Center
City
Okayama City
State/Province
Okayama
Country
Japan
Facility Name
The Sakakibara Heart Institute of Okayama
City
Okayama City
State/Province
Okayama
Country
Japan
Facility Name
Ohama Daiichi Hospital
City
Naha City
State/Province
Okinawa
Country
Japan
Facility Name
Nakagami Hospital
City
Okinawa City
State/Province
Okinawa
Country
Japan
Facility Name
Okinawa Nanbu Tokushukai Hospital
City
Shimajiri-gun
State/Province
Okinawa
Country
Japan
Facility Name
Urasoe General Hospital
City
Urasoe City
State/Province
Okinawa
Country
Japan
Facility Name
Kawachi General Hospital
City
Higashi Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Kansai Medical University Hirakata Hospital
City
Hirakata City
State/Province
Osaka
Country
Japan
Facility Name
Kansai Medical University Takii Hospital
City
Moriguchi City
State/Province
Osaka
Country
Japan
Facility Name
Komatsu General Hospital
City
Neyagawa City
State/Province
Osaka
Country
Japan
Facility Name
Higashi-sumiyoshi Morimoto Hospital
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Nissay Hospital
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Osaka City General Hospital
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Osaka City University, Graduate School of Medicine
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Osaka Ekisaikai Hospital
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Osaka General Hospital of West Japan Railway Campany
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Osaka General Medical Center
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Osaka Gyoumeikan Hospital
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Osaka Police Hospital
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Sakurabashi Watanabe Hospital
City
Osaka City
State/Province
Osaka
Country
Japan
Facility Name
Bell Land General Hospital
City
Sakai City
State/Province
Osaka
Country
Japan
Facility Name
Mimihara General Hospital
City
Sakai City
State/Province
Osaka
Country
Japan
Facility Name
National Cerebral and Cardiovascular Center
City
Suita City
State/Province
Osaka
Country
Japan
Facility Name
Osaka University Graduate School of Medicine
City
Suita City
State/Province
Osaka
Country
Japan
Facility Name
Saiseikai Senri Hospital
City
Suita City
State/Province
Osaka
Country
Japan
Facility Name
Hokusetsu General Hospital
City
Takatsuki City
State/Province
Osaka
Country
Japan
Facility Name
Midorigaoka Hospital
City
Takatsuki City
State/Province
Osaka
Country
Japan
Facility Name
Department of Cardiovascular Medicine, Saga University
City
Saga City
State/Province
Saga
Country
Japan
Facility Name
Mashiko Hospital
City
Kawaguchi City
State/Province
Saitama
Country
Japan
Facility Name
Saitama Medical Center, Jichi Medical University
City
Saitama City
State/Province
Saitama
Country
Japan
Facility Name
Kusatsu Heart Center
City
Kusatsu City
State/Province
Shiga
Country
Japan
Facility Name
Shiga Medical Center for Adults
City
Moriyama City
State/Province
Shiga
Country
Japan
Facility Name
Omihachiman Community Medical Center
City
Omihachiman City
State/Province
Shiga
Country
Japan
Facility Name
Biwako Ohashi Hospital
City
Otsu City
State/Province
Shiga
Country
Japan
Facility Name
Hamamatsu Medical Center
City
Hamamatsu City
State/Province
Shizuoka
Country
Japan
Facility Name
Seirei Hamamatsu General Hospital
City
Hamamatsu City
State/Province
Shizuoka
Country
Japan
Facility Name
Juntendo University Shizuoka Hospital
City
Izunokuni City
State/Province
Shizuoka
Country
Japan
Facility Name
Tokushima Red Cross Hospital
City
Komatsujima City
State/Province
Tokushima
Country
Japan
Facility Name
Ayase Heart Hospital
City
Adachi-ku
State/Province
Tokyo
Country
Japan
Facility Name
Juntendo University Hospital
City
Bunkyo-ku
State/Province
Tokyo
Country
Japan
Facility Name
The University of Tokyo Hospital
City
Bunkyo-ku
State/Province
Tokyo
Country
Japan
Facility Name
St. Luke's International Hospital
City
Chuo-ku
State/Province
Tokyo
Country
Japan
Facility Name
Sakakibara Heart Institute
City
Fuchu City
State/Province
Tokyo
Country
Japan
Facility Name
Tokyo Metroporitan Tama Medical Center
City
Fuchu City
State/Province
Tokyo
Country
Japan
Facility Name
Itabashi Chuo Medical Center
City
Itabashi-ku
State/Province
Tokyo
Country
Japan
Facility Name
Nihon University School of Medicine
City
Itabashi-ku
State/Province
Tokyo
Country
Japan
Facility Name
Teikyo University Hospital
City
Itabashi-ku
State/Province
Tokyo
Country
Japan
Facility Name
Tokyo Metroporitan Geriatric Hospital and Institute of Gerontology
City
Itabashi-ku
State/Province
Tokyo
Country
Japan
Facility Name
Toho University Medical Center Ohashi Hospital
City
Meguro-ku
State/Province
Tokyo
Country
Japan
Facility Name
The Cardiovascular Institute
City
Minato-ku
State/Province
Tokyo
Country
Japan
Facility Name
The Jikei University Hospital
City
Minato-ku
State/Province
Tokyo
Country
Japan
Facility Name
JR Tokyo General Hospital
City
Shibuya-ku
State/Province
Tokyo
Country
Japan
Facility Name
NTT Medical Center Tokyo
City
Shinagawa-ku
State/Province
Tokyo
Country
Japan
Facility Name
Tottri University
City
Yonago City
State/Province
Tottri
Country
Japan
Facility Name
Shuto General Hospital
City
Yanai City
State/Province
Yamaguchi
Country
Japan
Facility Name
Non-profit organization Associations for Establishiment of Evidence in Interventions
City
Minato-ku, Tokyo
ZIP/Postal Code
105-0013
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients

We'll reach out to this number within 24 hrs